SPIRIVA®
(tiotropium bromide)

NAME OF THE MEDICINE

SPIRIVA powder for inhalation capsules contain tiotropium 18 micrograms, equivalent to tiotropium bromide monohydrate 22.5 micrograms. The powder for inhalation capsules are used with the HandiHaler device.

DESCRIPTION

Chemical name: 3-Oxa-9-azoniatricyclo[3.3.1.0².⁴]nonane, 7-[(hydroxydi-2-thiencylacetyl)oxy]-9,9-dimethyl-, bromide, monohydrate, (1α, 2β, 4β, 5α, 7β)-
Molecular formula: C₁₉H₂₂NO₄S₂Br.H₂O
Molecular weight: 490.4 (monohydrate)
CAS number: 139404-48-1

Tiotropium bromide is a white to yellowish-white, odourless crystalline powder. It exists as a quaternary ammonium salt, and there are no ionisable functional groups on the molecule. The active substance is not optically active.

Tiotropium bromide is freely soluble in dimethyl sulphoxide, soluble in methanol, sparingly soluble in water and practically insoluble in methylene chloride. The solubility in aqueous solutions at room temperature is approx. 2.5%, independent of pH. At pH 7.4, the apparent partition coefficient (log P_{app}) is -2.25.

A monohydrate form of tiotropium bromide is produced by the synthetic process. The compound melts with decomposition between 225°C and 235°C, when determined by differential scanning calorimetry at a heating rate of 10 K per minute.

PHARMACOLOGY

Tiotropium is a long-acting, specific antimuscarinic (anticholinergic) agent. It has similar affinity to the muscarinic receptor subtypes M₁ to M₅ (K_D 5-41 pM). In the airways, inhibition by tiotropium of M₃-receptors at the smooth muscle results in relaxation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors. In preclinical in vitro as well as in vivo studies, bronchoprotective effects were dose-dependent.
Bronchoprotective effects lasting at least 24 hours were observed in some of the in vivo studies. The long duration of effect of tiotropium is likely to be due to its slow dissociation from M3-receptors. Tiotropium exhibited a significantly longer dissociation half-life from M3 receptors than ipratropium.

Tiotropium, a N-quaternary anticholinergic agent, is topically (broncho-) selective when administered by inhalation. The high potency (IC<sub>50</sub> approximately 0.4 nM for M3) and slow receptor dissociation is associated with a significant and long-acting bronchodilation in patients with chronic obstructive pulmonary disease (COPD).

The bronchodilation following inhalation of tiotropium is primarily a local effect on the airways, not a systemic one.

**PHARMACOKINETICS**

**Absorption**

Generally with the inhaled route of administration, the majority of the delivered dose is swallowed and deposited in the gastrointestinal tract, and to a lesser extent is delivered to the lungs.

Following inhalation in young healthy volunteers, the absolute bioavailability of 19.5% suggests that the proportion reaching the lung is highly bioavailable. The bioavailability is the apparent bioavailability, which is dependent upon the amount of tiotropium that is effectively inhaled. It is expected from the chemical structure of the compound that tiotropium is poorly absorbed from the gastro-intestinal tract. This was confirmed in a study in young healthy volunteers, with a low bioavailability of 2-3% for oral solutions. Food is not expected to influence the absorption of tiotropium for the same reason. At steady state, tiotropium plasma levels in COPD patients at peak were 17-19 pg/mL, when measured 5 minutes after inhalation of a 18 micrograms dose, and decreased rapidly in a multi-compartmental manner. Tiotropium demonstrates linear pharmacokinetics in the therapeutic range after intravenous administration and dry powder inhalation.

After chronic, once daily inhalation by COPD patients, pharmacokinetic steady state was reached after 2-3 weeks with no accumulation thereafter. Steady state trough plasma concentrations were 3-4 pg/mL.

**Distribution**

Studies in rats have shown that tiotropium does not penetrate the blood-brain barrier to any relevant extent. In plasma, 72% of tiotropium is bound to plasma proteins and shows a volume of distribution of 32 L/kg.

**Metabolism**

Metabolism does not occur to any great extent in young healthy volunteers, as indicated by 74% renal excretion of unchanged drug after an intravenous dose. The major metabolic pathway is non-enzymatic ester cleavage to the alcohol N-methylscopine and dithienylglycolic acid that are inactive on muscarinic receptors.

*In vitro* metabolism: In studies in animals and *in vitro* experiments with human liver microsomes and hepatocytes, minor amounts of a variety of glutathione conjugates, after oxidation of the thiophene rings, were observed.
In vitro studies in human liver microsomes revealed that the enzymatic pathway, relevant for only a small amount of tiotropium metabolism, can be inhibited by cytochrome P450 (CYP) 2D6 inhibitor quinidine and CYP 3A4 inhibitors ketoconazole and gestodene.

Tiotropium, even in supra-therapeutic concentrations, does not inhibit CYP 1A1, 1A2, 2B6, 2C9, 2C19, 2D6, 2E1 or 3A in human liver microsomes.

**Excretion**

Urinary excretion of unchanged substance in young healthy volunteers is 74% of an intravenous dose. Following inhalation of tiotropium, urinary excretion is 14% of the dose, the remainder being mainly non-absorbed drug in the gut that is eliminated via the faeces. Total clearance was 880 mL/min after an intravenous dose in young healthy volunteers with an interindividual variability of 22%. The renal clearance of tiotropium exceeds the creatinine clearance, indicating secretion into the urine. The terminal elimination half-life of tiotropium is between 5 and 6 days following inhalation.

As expected for all predominantly renally excreted drugs, advanced age was associated with a decrease of tiotropium renal clearance (326 mL/min in COPD patients <58 years to 163 mL/min in COPD > 70 years) which may be explained by decreased renal function. Tiotropium excretion in urine after inhalation decreased from 14% (young healthy volunteers) to about 7% (COPD patients), however plasma concentrations did not change significantly with advancing age within COPD patients if compared to inter- and intra-individual variability (43% increase in AUC\(_{0-4h}\) after dry powder inhalation).

In common with all other drugs that undergo predominantly renal excretion, renal impairment was associated with increased plasma drug concentrations and reduced renal drug clearance after both intravenous infusion and dry powder inhalations. Mild renal impairment (CL\(_{\text{CR}}\) 50-80 mL/min), which is often seen in elderly patients, increased tiotropium plasma concentrations slightly (39% increase in AUC\(_{0-4h}\) after intravenous infusion). In COPD patients with moderate to severe renal impairment (CL\(_{\text{CR}}\) <50 mL/min), the intravenous administration of tiotropium resulted in a doubling of the plasma concentrations (82% increase in AUC\(_{0-4h}\)), which was confirmed by plasma concentrations after dry powder inhalation.

There are no data on the pharmacokinetics of tiotropium in hepatic impairment. Liver insufficiency is not expected to have any relevant influence on tiotropium pharmacokinetics. Tiotropium is predominantly cleared by renal elimination (74% in young healthy volunteers) and by simple non-enzymatic ester cleavage to products that do not bind to muscarinic receptors.

**CLINICAL TRIALS**

**SPIRIVA HandiHaler**

The pivotal clinical development program consisted of four one-year randomised, double-blind studies; two placebo-controlled and two with an active control (ipratropium) in 1456 COPD patients, 906 of which received SPIRIVA. The studies assessed lung function in terms of forced expiratory volume in one second (FEV\(_1\)), forced vital capacity (FVC) and peak expiratory flow rate (PEFR). Health outcome measures including dyspnoea, exacerbations, hospitalisations and health-related quality of life (as measured by the St George’s Respiratory Questionnaire, SGRQ) were also assessed. In addition, the
development program included two large trials of six months duration which compared the bronchodilator efficacy and safety of SPIRIVA, with salmeterol inhalation aerosol and placebo in patients with COPD. These two studies randomised a total of 1207 patients, with approximately one-third treated with SPIRIVA.

Lung function

Overall results from the four one-year studies demonstrated that SPIRIVA, administered once daily, provided significant improvement in lung function (FEV₁ and FVC) within 30 minutes following the first dose and that this improvement was maintained for 24 hours. Pharmacodynamic steady state was reached within one week, with near maximal bronchodilation observed by the third day. SPIRIVA significantly improved morning and evening PEFR as measured by the patient’s daily recordings. The bronchodilator effects of SPIRIVA were maintained throughout the one-year period of administration with no evidence of tolerance.

In the two one-year, randomised, double blind, placebo-controlled studies, 550 patients received SPIRIVA once daily and 371 patients received placebo. Mean differences in FEV₁ between SPIRIVA and placebo were highly statistically significant at all time points (p<0.0001). The mean trough FEV₁ at Day 92 (defined as the primary efficacy endpoint) was 0.14 L greater following SPIRIVA than placebo (p<0.0001) and remained significantly different from placebo throughout the one year observation period (p<0.0001). The FVC response generally paralleled that of FEV₁.

In the two one-year, randomised, double blind, ipratropium-controlled studies, 356 patients received SPIRIVA once daily and 179 patients received ipratropium, 2 puffs of 20 micrograms, four times a day. Mean differences in trough FEV₁ between SPIRIVA and ipratropium were highly statistically significant at all time points (p<0.0001). The mean trough FEV₁ on Day 92 was 0.14 L greater following SPIRIVA than ipratropium (p<0.0001). The FVC response generally paralleled that of FEV₁.

Dyspnoea

In the one-year trials, SPIRIVA significantly improved dyspnoea in patients, as evaluated using the Mahler Transitional Dyspnoea Index (TDI) and patient daily reported symptoms. Following treatment with SPIRIVA, the dyspnoea score improved significantly when compared to placebo, with changes in each domain, as well as the focal score, being highly statistically significant over one year (p<0.0002). The proportion of patients treated with SPIRIVA who achieved a TDI focal score change of at least 1 point over the one-year period, representing a clinically meaningful difference, was statistically greater than the proportion of patients treated with placebo (p<0.0001).

When compared to ipratropium, patients treated with SPIRIVA exhibited significantly less dyspnoea at each time point, and the proportion of patients achieving a difference of 1 point in the TDI focal score was significantly greater in the SPIRIVA group.

Exacerbations and hospitalisations

In the analysis of the pooled data from the four one-year studies, SPIRIVA significantly reduced both the number of COPD exacerbations and the number of hospitalisations associated with COPD exacerbations. In addition, time to first COPD exacerbation and to first hospitalisation associated with a COPD exacerbation was significantly prolonged.

In the placebo-controlled trials, the percentage of patients with at least one exacerbation during the treatment period was 36% in the SPIRIVA group and 42% in the placebo group (p=0.03); at least one hospitalisation for exacerbation occurred in 5.5% and 9.4% of patients
respectively (p=0.019). The number of exacerbations and hospitalisations associated with exacerbations (expressed as events per 100 patient years) were significantly fewer for patients treated with SPIRIVA compared to placebo (p=0.045 and p=0.019 respectively). Patients on SPIRIVA also spent significantly fewer days in hospital for exacerbations compared to placebo (p=0.023). The time to first exacerbation was significantly delayed in the SPIRIVA group relative to placebo (p=0.011). Overall, these data indicate that therapy with SPIRIVA is associated with a delayed onset and a lower incidence of COPD exacerbations.

In the ipratropium-controlled trials, the percentage of patients with an exacerbation during the treatment period was 35% in the SPIRIVA group and 46% in the ipratropium group, a difference that was statistically significant. A similar trend was seen for hospitalisations for exacerbation (7.3% vs. 11.7%; p=0.108). The number of exacerbations and exacerbation days impacted by these events was also less in the SPIRIVA group compared to ipratropium (p=0.006 and p=0.002, respectively). A similar trend was observed for hospitalisations (p=0.0803) and hospitalisation days for exacerbations (p=0.86). The time to first exacerbation, as well as for hospitalisation for exacerbation, was significantly delayed in the SPIRIVA group relative to the ipratropium group (p=0.008 and 0.048, respectively). Overall these data indicate that SPIRIVA is associated with reduced exacerbations.

SPIRIVA significantly reduced the percentage of patients experiencing one or more COPD exacerbations compared with placebo in a six-month randomised, double-blind, placebo-controlled trial of 1,829 patients with COPD (27.9% vs. 32.3%, respectively, p=0.0368). The mean number of exacerbations per patient-year was significantly lower in the SPIRIVA group compared to placebo (0.85 vs. 1.05, respectively, p=0.003), as was the number of exacerbation days (p<0.0001). Time to first exacerbation was significantly increased in the SPIRIVA group compared to placebo (relative risk = 0.834, p=0.034). Fewer SPIRIVA patients were hospitalised because of COPD exacerbation (7.0% vs. 9.5%, respectively; p = 0.056), although this difference was not statistically significant. The number of hospitalisations for exacerbations per patient-year was significantly lower in the SPIRIVA group, compared to placebo (p=0.013). Similarly, the mean number of hospitalisations days for exacerbations was lower in the SPIRIVA group compared to placebo (1.43 vs 1.70 days per patient-year, p=0.0013). The time to first hospitalisation for an exacerbation was significantly increased in the SPIRIVA group compared to placebo (relative risk = 0.723, p<0.05). See Figure 1.
Figure 1: Kaplan-Meier estimates of the probability of no hospitalisation due to COPD exacerbation.

Health related quality of life

The SGRQ was the primary instrument used to evaluate disease-specific health related quality of life, with the impact domain stated as the primary endpoint. SPIRIVA was significantly more effective than both placebo and ipratropium in improving health-related quality of life based on the SGRQ. The percentages of patients in the SPIRIVA groups who demonstrated a clinically meaningful improvement (pre-specified criteria of 4 units) over baseline were significantly greater than those in the placebo and ipratropium groups.

SPIRIVA was more effective than placebo in each domain. Generally, the difference between the treatment groups increased between baseline and the last treatment visit. For the primary measure, Impacts score, the difference between the two treatment groups ranged from 1.8 to 4.0 and was statistically significant \( p<0.05 \) on all test days.

A significantly greater \( p<0.05 \) percentage of patients in the SPIRIVA group showed a clinically meaningful improvement (drop of 4 units) in the Impacts score from six months through to the end of the study and for Total score from three months through to the end of the study.

SPIRIVA was also shown to be more effective than ipratropium in improving health-related quality of life using the SGRQ. For Impacts score, the difference between the two treatment groups in the mean score ranged from 0.6 at 8 days to 4.3 at 364 days and was statistically significant from three months through the end of the study. Statistically significant differences between SPIRIVA and ipratropium were also noted for the Total score on four of six test days.

A significantly greater \( p<0.05 \) percentage of patients in the SPIRIVA group showed clinically meaningful improvement (difference greater than 4 units) in both Impacts and Total scores over ipratropium after six months.
Two trials of six months duration compared the bronchodilator efficacy and safety of SPIRIVA once daily with salmeterol inhalation aerosol (50 micrograms twice daily) and placebo in patients with COPD. In one study, designed to evaluate the 12-hour duration of action, when the effects over time for SPIRIVA and salmeterol were compared, the mean trough FEV$_1$ in the SPIRIVA group was significantly higher than that in the salmeterol group (p<0.05), beginning on day 57. The difference between SPIRIVA and salmeterol for trough, average and peak FEV$_1$ response was statistically significant (p<0.05), except for trough response on day 15, and average and peak FEV$_1$ response on day 1. At the end of the study, trough FVC had improved in the SPIRIVA group significantly above the placebo (p<0.001) and the salmeterol (p<0.01) groups. At the end of the combined six months trials, the improvement in TDI focal scores for SPIRIVA above placebo was 1.1 units (p<0.001), which was both statistically and clinically significant, and for salmeterol above placebo was 0.7 units (p<0.05), which was not clinically significant.

**Exercise tolerance**

The impact of improvement in dyspnoea on functional activities was investigated in two randomised, double-blind, placebo-controlled, parallel group studies in 433 COPD patients. The studies investigated whether six weeks treatment with SPIRIVA once daily improves exercise tolerance in COPD patients as measured by symptom-limited exercise endurance time (ET) during constant work rate cycle ergometry at 75% of maximal work capacity. Results demonstrated that SPIRIVA significantly improved ET by 20% to 28% compared with placebo. Increases in ET (seconds) are shown in Table 1.

Additionally in these trials, SPIRIVA demonstrated significant reductions in lung hyperinflation at rest and significant reductions in lung hyperinflation and dyspnoea during constant work rate cycle exercise.

**Table 1**  
**Endurance time (ET) after 42 days treatment with tiotropium vs placebo in patients with COPD**

<table>
<thead>
<tr>
<th>Study</th>
<th>Pre-treatment Baseline ET (seconds)</th>
<th>Adjusted mean ET (seconds)</th>
<th>Treatment Difference tio – placebo at 42 days (seconds)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial A</td>
<td>492</td>
<td>640</td>
<td>535</td>
<td>105</td>
</tr>
<tr>
<td>Trial B</td>
<td>537</td>
<td>741</td>
<td>577</td>
<td>164</td>
</tr>
</tbody>
</table>

**QT interval**

In a dedicated QT study involving 53 healthy volunteers, SPIRIVA 18 mcg and 54 mcg (i.e. three times the therapeutic dose) over 12 days did not significantly prolong QT intervals of the ECG.

**UPLIFT trial**

In a 4-year trial of 5,993 patients, SPIRIVA did not alter the annualised rate of decline of FEV$_1$ (primary endpoint), but maintained improvements in the secondary endpoint of the difference in FEV$_1$ at clinic visits throughout 4 years (Figure 2).
A significantly higher proportion of patients in the tiotropium group than in the placebo group had an improvement of ≥ 4 units in the secondary endpoint of SGRQ total scores (i.e. exceeded the minimal clinically important difference) from baseline at 1 year (49% vs. 41%), 2 years (48% vs. 39%), 3 years (46% vs. 37%), and 4 years (45% vs. 36%) (p < 0.001 for all comparisons).

In the following secondary endpoints, tiotropium significantly delayed the time to the first exacerbation and significantly delayed the time to the first hospitalisation for an exacerbation. The Hazard Ratios (95% CI) for an exacerbation or exacerbation leading to hospitalisation were 0.86 (0.81, 0.91) and 0.86 (0.78, 0.95). Tiotropium was also associated with a reduction in the mean number of exacerbations of 14% (p<0.001). The mean numbers of exacerbations leading to hospitalisations were infrequent and did not differ significantly between the tiotropium and placebo groups.

During treatment, there was a 16% reduction in the risk of death. The incidence rate of death was 4.79 per 100 patient years in the placebo group vs. 4.10 per 100 patient years in the tiotropium group (hazard ratio (tiotropium/placebo) = 0.84, 95% CI = 0.73, 0.97).

For the 4-year, protocol-defined study period up to day 1440, the effect of tiotropium extended to end of treatment period. Among patients for whom vital-status information was available (95% of patients), 921 patients died: 14.4% in the tiotropium group and 16.3% in the placebo group (hazard ratio, 0.87; 95% CI, 0.76 to 0.99). During a period of 4 years plus 30 days (1470 days) included in the intention-to-treat analysis, 941 patients died: 14.9% in the tiotropium group and 16.5% in the placebo group (hazard ratio, 0.89; 95% CI, 0.79 to 1.02). Fewer vital status data were available for the day 1470 analyses (75% of patients). The effect became non-significant within the 30-day follow-up period, when according to protocol, patients were discontinued from their study medication.

**INDICATIONS**

SPIRIVA is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD). SPIRIVA is indicated for the prevention of COPD exacerbations.
CONTRAINDICATIONS

SPIRIVA is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, e.g. ipratropium or oxitropium or to any other component of this product (see list of excipients in Presentation and Storage Conditions).

PRECAUTIONS

SPIRIVA, as a once daily maintenance bronchodilator, should not be used for the treatment of acute episodes of bronchospasm, i.e. rescue therapy.

Immediate hypersensitivity reactions may occur after administration of SPIRIVA.

As with other anticholinergic drugs, SPIRIVA should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction. In a meta-analysis of placebo-controlled trials, SPIRIVA was associated with a non-significant increase in the risk of urinary retention, and a significant increase in the risk of micturition difficulties.

Inhaled medicines may cause inhalation-induced bronchospasm.

As with all predominantly renally excreted drugs, SPIRIVA use should be monitored closely in patients with moderate to severe renal impairment (creatinine clearance of ≤ 50 mL/min) (see Pharmacokinetics).

Patients must be instructed in the correct administration of SPIRIVA. Care must be taken not to allow the powder or spray to enter into the eyes. Eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema may be signs of acute narrow-angle glaucoma. Should any combination of these symptoms develop specialist advice should be sought immediately. Miotic eye drops are not considered to be effective treatment.

SPIRIVA should not be used more frequently than once daily (see Overdose).

SPIRIVA capsules are to be used only with the HandiHaler® device (see separate HandiHaler Directions for Use). This product contains 5.5 mg of lactose monohydrate per capsule.

Hepatic Impairment

There are no data on the use of tiotropium in patients with hepatic impairment. As tiotropium is primarily cleared by renal mechanisms, no dosage adjustment is recommended. However patients should be monitored closely.

Renal Impairment

Renally-impaired patients can use SPIRIVA at the recommended dose. However, as with all predominantly renally excreted drugs, SPIRIVA use should be monitored closely in patients with moderate to severe renal impairment.

Use in the elderly

Elderly patients can use SPIRIVA at the recommended dose. Renal clearance of tiotropium is likely to be slower in elderly patients (see Renal Impairment).
**Use in children**

The safety and effectiveness of SPIRIVA in paediatric patients has not been established. Therefore, SPIRIVA should not be used in paediatric patients.

**Carcinogenicity and genotoxicity**

Long-term carcinogenicity studies in mice and rats, with tiotropium (as bromide) administered by inhalation, showed no evidence of neoplastic responses. The highest doses studied were approximately 0.8x (male mouse), 38x (female mouse) and 16x (rat) greater than the maximum recommended human daily dose of 22.5 μg, based on body surface area. Tiotropium (as bromide) did not exhibit any genotoxic effects in assays for gene mutation (bacteria and mammalian cells *in vitro* and *in vivo* mouse micronucleus test) or DNA damage (rat hepatocytes *in vitro*).

**Impairment in fertility**

Tiotropium (as bromide) did not affect the fertility of male or female rats when administered by inhalation at doses up to 2 mg/kg (750x the maximum recommended human daily dose of 22.5 μg, based on body surface area).

**Use in Pregnancy: (Category B1)**

There are no adequate and well controlled studies with tiotropium (as bromide) in pregnant women. Reproductive toxicity studies with tiotropium bromide administered by inhalation to rats and rabbits at doses up to 2.0 and 0.5 mg/kg/day, respectively, produced no evidence of fetal malformations. These doses correspond to 750x and 400x the maximum recommended human daily dose of 22.5 μg based on body surface area. The animal studies do not suggest direct or indirect harmful effects with respect to embryo/fetal development, pregnancy, parturition or post-natal development.

For tiotropium bromide, no clinical data on its use during pregnancy are available. Tiotropium should be used in pregnancy only if the potential benefit exceeds the potential risk.

**Use in Lactation**

Clinical data from lactating women exposed to tiotropium are not available. Based on studies in lactating rats, a small amount of tiotropium is excreted in breast milk.

Therefore, tiotropium should not be used in lactating women unless the expected benefit outweighs any possible risk to the infant.

**Interactions with Other Medicines**

Although no formal drug interaction studies have been performed, tiotropium has been used concomitantly with other drugs which are commonly used in the treatment of COPD, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids without clinical evidence of drug interactions.

Limited information about co-administration of other anticholinergic medicines with SPIRIVA is available from a clinical trial. Acute single dose administration of ipratropium bromide after 19 days of SPIRIVA treatment in healthy volunteers (n=35) was not associated with relevant changes in vital signs or electrocardiographic findings. Adverse events were reported by 3 (9%) of subjects in the study during ipratropium treatment with tiotropium compared to 1
(3%) during placebo treatment with tiotropium. Ipratropium was associated with a 16% decrease in salivary secretions in healthy volunteers. Chronic co-administration of other anticholinergic medicines with SPIRIVA has not been studied and is therefore not recommended.

Effects on ability to drive or operate machinery

No studies on the effects on the ability to drive and use machines have been performed. The occurrence of dizziness or blurred vision may influence the ability to drive and use machinery.

ADVERSE EFFECTS

SPIRIVA HandiHaler

Many of the listed undesirable effects can be assigned to the anticholinergic properties of tiotropium.

Adverse drug reactions were identified from data obtained in clinical trials and spontaneous reporting during post approval use of the drug. The clinical trial database includes 9,149 tiotropium patients from 26 placebo-controlled clinical trials with treatment periods ranging between four weeks and four years, contributing 11,958 person years of exposure to tiotropium.

Metabolism and nutrition disorders:
not known: dehydration

Nervous system disorders:
≥ 0.1% and < 1%: dizziness
≥ 0.01% and < 0.1%: insomnia

Eye disorders:
≥ 0.1% and < 1%: blurred vision
≥ 0.01% and < 0.1%: increased intraocular pressure, glaucoma

Cardiac disorders:
≥ 0.1% and < 1%: atrial fibrillation
≥ 0.01% and < 0.1%: tachycardia, palpitations, supraventricular tachycardia

Respiratory, thoracic and mediastinal disorders:
≥ 0.1% and < 1%: dysphonia, cough, pharyngitis,
≥ 0.01% and < 0.1%: bronchospasm, epistaxis, laryngitis, sinusitis

Gastrointestinal disorders:
≥ 1% and < 10%: dry mouth, usually mild
≥ 0.1% and < 1%: constipation, gastro-oesophageal reflux disease, stomatitis
≥ 0.01% and < 0.1%: dysphagia, gingivitis, glossitis, intestinal obstruction including paralytic ileus, oropharyngeal candidiasis

Skin and subcutaneous tissue disorders, Immune system disorders:
≥ 0.1% and < 1%: rash
≥ 0.01% and < 0.1%: urticaria, pruritus, hypersensitivity (including immediate reactions)
not known: angioneurotic oedema, skin infection, skin ulcer, dry skin

Musculoskeletal and connective tissue disorders:
not known: joint swelling
Renal and urinary disorders:
> 0.1% and <1%: dysuria, urinary retention (usually in men with predisposing factors)
≥ 0.01% and < 0.1%: urinary tract infection

**DOSAGE AND ADMINISTRATION**

**SPIRIVA HandiHaler**

The recommended dosage of SPIRIVA is inhalation of the contents of one capsule, once daily with the HandiHaler device, at the same time each day (see HandiHaler instructions for use).

SPIRIVA capsules must not be swallowed.

**OVERDOSAGE**

High doses of tiotropium may lead to anticholinergic signs and symptoms.

However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 282 micrograms tiotropium in healthy volunteers. Additionally, no relevant adverse effects, beyond dry mouth, were observed following 7 day dosing of up to 141 micrograms tiotropium in healthy volunteers. In a multiple dose study in COPD patients, with a maximum daily dose of 36 micrograms tiotropium over four weeks, no significant undesirable effects were observed.

Acute intoxication by inadvertent oral ingestion of tiotropium powder is unlikely, due to low oral bioavailability.

**PRESENTATION AND STORAGE CONDITIONS**

**SPIRIVA powder for inhalation in capsules**

Each hard gelatine SPIRIVA capsule contains 18 micrograms tiotropium, equivalent to 22.5 micrograms tiotropium bromide (monohydrate) and the excipient lactose (which contains milk protein).

SPIRIVA capsules are light green in colour, with the product code (TI 01) and company logo printed on the capsule. The capsules contain a white powder.

SPIRIVA capsules are presented in Aluminium / PVC / Aluminium blister packs.

Available in cartons containing 30 capsules.

**In-use shelf life**

SPIRIVA capsules for inhalation - Use within 5 days of opening each blister strip of 5 capsules.

**Special precautions for storage**

SPIRIVA capsules for inhalation - Do not store above 25°C. Do not freeze. Avoid storage in direct sunlight or heat.
NAME AND ADDRESS OF THE SPONSOR

BOEHRINGER INGELHEIM PTY LIMITED¹
ABN 52 000 452 308
78 WATERLOO ROAD
NORTH RYDE NSW 2113

PFIZER AUSTRALIA PTY LTD
ABN 50 008 422 348
38-42 WHARF ROAD
WEST RYDE NSW 2114

¹Sponsor

POISON SCHEDULE OF THE MEDICINE

S4 – Prescription Only Medicine

DATE OF APPROVAL

Date of TGA approval: 01 July 2010